CHRONOPHARMACOLOGICAL FEATURES OF SILIMARIN’S HEPATOPROTECTOCAL ACTIVITY UNDER PARACETAMOL HEPATITIS IN RATS

  • K. O. Kalko National University of Pharmacy (Kharkiv)
  • S. M. Drogovoz National University of Pharmacy (Kharkiv)
  • O. Ya. Mishchenko
  • L. B. Ivantsyk National University of Pharmacy (Kharkiv)
  • K. O. Dehtiarova National University of Pharmacy (Kharkiv)
  • М. М. Lukashuk Municipal institution of higher education «Rivne medical academy» of Rivne region council (Rivne)
  • I. М. Lukashuk Municipal institution of higher education «Rivne medical academy» of Rivne region council (Rivne)
  • O. V. Gerush Higher State Educational Establishment of Ukraine "Bukovinian State Medical University" (Chernivtsi)
  • A. O. Palamar Higher State Educational Establishment of Ukraine "Bukovinian State Medical University" (Chernivtsi)
  • O. N. Korovenkova Higher State Educational Establishment of Ukraine "Bukovinian State Medical University" (Chernivtsi)
  • S. I. Shevchenko National University of Pharmacy (Kharkiv)
Keywords: daily (circadian) rhythms; silymarin; liver toxicity; paracetamol hepatitis.

Abstract

Determination of dependence of the efficiency and toxicity of drugs on the time of day or season is one of the most promising areas of modern experimental and clinical pharmacology. The aim of the study. Aim is to identify features of daily rhythms of silymarin influence on the state of antioxidant/prooxidant and cytolytic processes (the leading link in the implementation of hepatoprotective activity) with paracetamol in rats under conditions of acute toxic liver damage. Materials and methods. Chronopharmacological action features of silymarin were studied by use of the generic drug "Karsil" as an example (Sopharma, Bulgaria) with paracetamol in rats under conditions of acute toxic liver damage. The state of the processes of POL-AOS was evaluated by the content of TBA-active products (TBA-AP), the content of recovered glutathione, the activity of SOD, catalase in hepatocytes, and the cytolytic processes by the activity of ALT in serum. Results. There was established a certain chronoarchitectonics of the rhythms of the antioxidant protection system and the activity of the processes of peroxidation in rats under physiological conditions, which was not disturbed by paracetamol on the background of acute liver damage (with the exception of level of acrophase catalase activity). The same dynamics and commonality of rhythms occurred on the background of the use of silymarin. The maximum display of silymarin hepatoprotective activity was observed under conditions of its use in the morning (09.00) and in the evening (21.00). Conclusions. The use of silymarin during periods of maximal display of its hepatoprotective activity, in the morning (09.00) and in the evening (21.00) may be the way to increase its bioavailability. Chronopharmacological features of silymarin activity have been established and should be taken into account when to conduct its further chronopharmacological studies.

Downloads

Download data is not yet available.

References

Bunyatyan N. D., Kal'ko E. A., Drogovoz S. M. i dr. Hronofarmakologicheskie osobennosti dejstviya gepatoprotektorov v eksperimente // Byul. eksperiment. biologii i mediciny. – 2018. – N 6. – S. 712-715. DOI: 10.1007/s10517-018-4258-8

Doklіnіchnі doslіdzhennya lіkars'kih zasobіv: Metod. rekomendacії / O. V. Stefanov іn.; za red. chl-kor. AMN Ukraїni O. V. Stefanova. – K.: Avіcena, 2001. – 528 p.

Drogovoz S. M., Shtrygol' S. Yu., Rapoport S. I. i dr. Hronofarmakologiya dlya vracha, provizora, studenta: Uch.-spravochnik / Pod red. S. M. Drogovoz. – Har'kov: Titul, 2016. – 376 p.

Drogovoz S. M., Gudzenko A. P., Butko Ya. A. Pobochnoe dejstvie lekarstv: Uchebnik-spravochnik. – Har'kov: SIM, 2015. – 480 p.

Kal'ko E. A., Drogovoz S. M., Pozdnyakova A. Yu., Zaharko N. V. Cirkadiannaya zavisimost' toksichnosti paracetamola u krys // Eksperimental'naya i klinicheskaya farmakologiya. – 2016. – T. 79, № 7. – P. 25–28.

Kal'ko K. O. Hronofarmakologіchne doslіdzhennya aktivnostі gepatoprotektornih zasobіv: Avtoref. dis. ... kand. farmac. Nauk. – H., 2017. – 36 p.

Kal'ko K. O., Drogovoz S. M. Dobova zalezhnіst' gepatoprotektornoї aktivnostі antralyu na modelі gostrogo paracetamolovogo gepatitu u shchurіv // Farmakologіya ta lіkars'ka toksikologіya. – 2017. – Vip. 54, № 2. – P. 62–68.

Kal'ko K. O., S. M. Drogovoz, N. V Zaharko ta іn. Vpliv toksichnih doz paracetamolu na cirkadіannij ritm prooksidantno-antioksidantnogo gomeostazu // Farmakologіya ta lіkars'ka toksikologіya. – 2016. – Vip. 47, № 1. – P. 81–86.

Karsil®: instrukciya k medicinskomu naznacheniyu. – Rezhim dostupa: https://compendium.com.ua/info/11819/karsil-sup-sup-/?term=%D0%9A%D0%90%D0%A0%D0%A1%D0%98%D0%9B

Klinicheskaya laboratornaya diagnostika: metody i traktovka laboratornyh issledovanij / Pod red. prof. V. S. Kamyshnikova. – M.: MED-press-inform, 2017. – 720 p.

Korolyuk M. A., Ivanova L. I., Majorova I. G., Tokarev V. E. Metod opredelenie aktivnosti katalazy // Laboratornoe delo. – 1988. – № 1. – P. 16–19.

Matveev A. V. Gepatoprotektory. Analiz mezhdunarodnyh issledovanij po preparatam gruppy lekarstv dlya pecheni. – Simferopol': IT «Arial», 2013. – 384 p.

Metodicheskie ukazaniya dlya vypolneniya eksperimental'nyh issledovanij po bol'shomu special'nomu praktikumu «Metody ocenki sostoyaniya oksidantnoj i antioksidantnoj sistem biologicheskih ob"ektov» / S. S. CHernadchuk, Fedorko N. L., Zaharieva Z. E. i dr. – Odessa, 2010. – 52 p.

Nobelevskuyu premiyu po fiziologii i medicine prisudili za issledovanie cirkadnyh ritmov. – Rezhim dostupa: https://nplus1.ru/news/2017/10/02/medicine2017

Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv / Pod red. A. N. Mironova. – M.: Grif i K, 2013. – CH. 1. – 944 p.

Sirota T. V. Novyj podhod v issledovanii processa autookisleniya adrenalina i ispol'zovanie ego dlya izmereniya aktivnosti SOD // Voprosy med. himii. – 1999. – № 3. – P. 263–272.

Stal'naya I. D., Garishvili T. G. Metod opredeleniya malonovogo dial'degida s pomoshch'yu tiobarbiturovoj kisloty / Sovremennye metody v biohimii. – M.: Medicina, 1977. – P. 44–46.

Truhacheva N. V. Matematicheskaya statistika v mediko-biologicheskih issledovaniyah s primeneniem paketa Statistica. – M.: GEOTAR-Media, 2012. – 379 p.

Bahmani M, Shirzad H, Rafieian et al. Silybum marianum: beyond hepatoprotection // J. Evid. Based. Complementary Altern. Med. –2015. – Vol. 20. – P. 292–301. doi:10.1177/2156587215571116.

Bunchorntavakul C., Reddy K. R. Acetaminophen-related hepatotoxicity // Clin. Liver Dis. – 2013. – Vol. 17, N 4. – Р. 587–607.

Dallmann R., Brown S. A., Gachon F. Chronopharmacology: new insights and therapeutic implications // Annu Rev. Pharmacol. Toxicol. – 2014. – Vol. 54. – Р. 339–361. doi: 10.1146/annurev-pharmtox-011613-135923.

Francini-Pesenti Francesco, Spinella Paolo, Calò Lorenzo A. Potential role of phytochemicals in metabolic syndrome prevention and therapy Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. – 2019. – Vol. 12. – P. 1987–2002.

Gravier-Hernández Rosario, Valle Lizette Gil-del, Valdes-Alons Lindunka et al. Oxidative stress in hepatitis C virus – human immunodeficiency virus co-infected patients // Annals of Hepatology. – 2019. – Vol. 19. – P. 92–98.

Kangari Parisa, Farahany Tahereh Zarnoosheh, Golchin Ali et al. Enzymatic Antioxidant and Lipid Peroxidation Evaluation in the Newly Diagnosed Breast Cancer Patients in Iran // Asian Pacific J. of Cancer Prevention. – Vol 19. – P. 3511–2515.

Lv Hongming, An Beiying, Yu Qinlei et al. The hepatoprotective effect of myricetin against lipopolysaccharide and D-galactosamine-induced fulminant hepatitis // Int. J. Biol. Macromol. – 2019 Nov 8. pii: S0141-8130(19)36974-0. doi: 10.1016/j.ijbiomac.2019.11.075.

Mishchenko O. Ya., Kalko K. O. , Zolotaikina M. Yu. et al. Hepatoprotective and choleretic activity of dried extract of Tanacetum vulgare flowers // Thai J. of Pharmaceutical Sciences. – 2019. – Vol. 43, N 1. – Р. 30–35.

Ohdo Shigehiro, Koyanagi Satoru, Matsunaga Naoya. Chronopharmacological strategies focused on chrono-drug discovery // Pharmacology & Therapeutics. – 2019. – Vol. 202. – P. 72–90.

Piazzini Vieri, Micheli Laura, Luceri Cristina et al. Nanostructured lipid carriers for oral delivery of silymarin: Improving its absorption and in vivo efficacy in type 2 diabetes and metabolic syndrome model // International J. of Pharmaceutics. – 2019. – Vol. 572 – 118838 https://doi.org/10.1016/j.ijpharm.2019.118838

Rousar Т., Kucera O., Krivakova P. et al. Evaluation of oxidative status in acetaminophen treated rat hepatocyes in culture // Physiol Res. – 2009. – Vol. 58. – Р. 239–246.

Sevastianos V. A, Voulgaris T. A, Dourakis S. P. Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases // Expert Rev. Gastroenterol. Hepatol. – 2020. – Vol. 14, N 1. – P. 27–37. doi: 10.1080/17474124.2020.1708191. Epub 2019 Dec 26.

Tajmohammadi A., Razavi B. M., Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review // Phytother Res. – 2018. – Vol. 32, N 10. – P. 1933–1949. doi: 10.1002/ptr.6153. Epub 2018 Jul 17.

Vargas-Mendoza Nancy, Eduardo Madrigal Santillan, Angel Morales Conzalez et al. Hepatoprotective effect of silymarin // World J. Hepatol. – 2014. – N 3. – P. 144–149.

Yang Z., Liping Zhuang, Yunfei Lu et al. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials // Biomed. Res. Int. – 2014. – N 12. – Р. 41–85.

Zmrzljak U. P., Rozman D. Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: The time matters // Chem. Res. – 2012. – Vol. 25. – P. 811–882.


Abstract views: 54
PDF Downloads: 76
Published
2020-03-30
How to Cite
Kalko, K. O., Drogovoz, S. M., Mishchenko, O. Y., Ivantsyk, L. B., Dehtiarova, K. O., LukashukМ. М., LukashukI. М., Gerush, O. V., Palamar, A. O., Korovenkova, O. N., & Shevchenko, S. I. (2020). CHRONOPHARMACOLOGICAL FEATURES OF SILIMARIN’S HEPATOPROTECTOCAL ACTIVITY UNDER PARACETAMOL HEPATITIS IN RATS. Likars’ka Sprava, (1-2), 63-71. https://doi.org/10.31640/JVD.1-2.2020(9)
Section
Experimental Study